Nanovibronix (NASDAQ:NAOV) Releases Quarterly Earnings Results

Nanovibronix (NASDAQ:NAOV) released its quarterly earnings data on Friday. The company reported ($0.91) EPS for the quarter, FiscalAI reports. Nanovibronix had a negative return on equity of 45.24% and a negative net margin of 380.29%.The business had revenue of $0.72 million during the quarter.

Nanovibronix Stock Performance

Shares of NASDAQ NAOV traded down $0.27 during midday trading on Friday, hitting $4.42. 6,978 shares of the company’s stock traded hands, compared to its average volume of 511,755. Nanovibronix has a 1 year low of $4.40 and a 1 year high of $162.50. The stock has a market capitalization of $4.47 million, a price-to-earnings ratio of -0.05 and a beta of 2.16. The firm has a fifty day moving average of $6.00 and a 200 day moving average of $10.49.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nanovibronix in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

About Nanovibronix

NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.